KCI, an Acelity Company, announced the launch of ABTHERA Open Abdomen Negative Pressure Therapy in Japan, expanding access to the Company’s surgical portfolio in the country.
Image: KCI Asia-Pacific Team Ends 2018 with Big Showings at Key Conferences. Photo: Courtesy of KCI Licensing, Inc.
ABTHERA Therapy is a temporary abdominal closure system that allows surgeons to take control in managing challenging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary.
“When dealing with patients managed with damage control for severe abdominal hemorrhage, abdominal compartment syndrome or severe peritonitis, using ABTHERA Therapy has been shown to be associated with proven patient outcomes,” said Dr. Demetrios Demetriades, Professor of Surgery, Keck USC School of Medicine and the Director of the USC Division of Trauma, Emergency Surgery and Surgical Intensive Care Unit. “With the introduction of ABTHERA Therapy in Japan, clinicians now have a clinically demonstrated solution for a previously unmet, significant need, that manages the open abdomen at critical times, helping to achieve primary fascial closure more quickly.”
ABTHERA Therapy is supported by robust clinical evidence and is associated with improved outcomes, including increased patient survival, improved primary fascial closure rates, lower intensive care unit stays when compared to Barker’s vacuum-packing technique (BVPT). In one open label, prospective observational study of 168 patients (111 ABTHERA Therapy vs. 57 BVPT), ABTHERA Therapy patients were more likely to achieve primary fascial closure and had a reduction in 30-day all-cause mortality compared to patients who received BVPT (14% ABTHERA Therapy vs. 30% BVPT; p=0.01).1
“Japan is one of the largest healthcare markets in the world, and this launch fills a significant unmet need, allowing us to better support clinicians and their patients in the operating room,” said R. Andrew Eckert, President and Chief Executive Officer of KCI. “We are able to deliver leading-edge technologies like ABTHERA Therapy by expanding upon our unparalleled expertise in wound care to innovate new solutions for our customers.”
ABTHERA Therapy is designed to:
Actively remove fluid and help reduce edema
Provide medial tension, which helps minimize fascial retraction and loss of domain
Help protect abdominal contents from external environment
Provide separation between the abdominal wall and viscera, protecting abdominal contents
Allow rapid access for re-entry and does not require sutures for placement
KCI Chief Medical Officer Ron Silverman, M.D., F.A.C.S., added, “We have witnessed the demonstrated success of ABTHERA™ Therapy through countless clinical and retrospective studies around the globe. We are thrilled to be able to introduce this technology to clinicians in Japan through a series of educational lectures at several leading universities on the use of ABTHERA Therapy.”
Dr. Demetrios Demetriades led the lecture series and capped off his Japanese tour with a keynote address at the ABTHERA Therapy launch event on February 16 in Tokyo.
Source: Company Press Release